Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography
- Elasmogen Ltd., Aberdeen (United Kingdom)
- Univ. of Wisconsin, Madison, WI (United States). School of Medicine and Public Health
- Univ. of Wisconsin, Madison, WI (United States). School of Medicine and Public Health; Medical School of Wisconsin, Milwaukee, WI (United States)
- Medical School of Wisconsin, Milwaukee, WI (United States)
- Univ. of Minnesota Medical School, Minneapolis, MN (United States); Univ. of Minnesota, Minneapolis, MN (United States)
- Univ. of Minnesota, Minneapolis, MN (United States)
- Univ. of Minnesota Medical School, Minneapolis, MN (United States)
- Cornell Univ., Lemont, IL (United States). Advanced Photon Source (APS)
- Elasmogen Ltd., Aberdeen (United Kingdom); Univ. of Aberdeen (United Kingdom)
Single-domain Variable New Antigen Receptors (VNARs) from the immune system of sharks are the smallest naturally occurring binding domains found in nature. Possessing flexible paratopes that can recognize protein motifs inaccessible to classical antibodies, VNARs have yet to be exploited for the development of SARS-CoV-2 therapeutics. Here, we detail the identification of a series of VNARs from a VNAR phage display library screened against the SARS-CoV-2 receptor binding domain (RBD). The ability of the VNARs to neutralize pseudotype and authentic live SARS-CoV-2 virus rivalled or exceeded that of full-length immunoglobulins and other single-domain antibodies. Crystallographic analysis of two VNARs found that they recognized separate epitopes on the RBD and had distinctly different mechanisms of virus neutralization unique to VNARs. Structural and biochemical data suggest that VNARs would be effective therapeutic agents against emerging SARS-CoV-2 mutants, including the Delta variant, and coronaviruses across multiple phylogenetic lineages. This study highlights the utility of VNARs as effective therapeutics against coronaviruses and may serve as a critical milestone for nearing a paradigm shift of the greater biologic landscape.
- Research Organization:
- Argonne National Laboratory (ANL), Argonne, IL (United States)
- Sponsoring Organization:
- NIH; USDOE Office of Science (SC)
- OSTI ID:
- 1841247
- Journal Information:
- Nature Communications, Journal Name: Nature Communications Journal Issue: 1 Vol. 12; ISSN 2041-1723
- Publisher:
- Nature Publishing GroupCopyright Statement
- Country of Publication:
- United States
- Language:
- ENGLISH
Similar Records
A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies